For instance, dual inhibition of MYC targets PD-L1 and CTLA-4 reverses MYC-driven immunosuppression through pro-inflammatory macrophages in hepatocellular carcinoma (115). The gene discussed is MYC; the disease is hepatocellular carcinoma.